Henry Schein Non-GAAP EPS of $1.56 beats by $0.20, revenue of $3.5B beats by $20M (HSIC:NASDAQ)
Henry Schein reported Q3 Non-GAAP EPS of $1.56, beating estimates by $0.20, with revenue of $3.5B, up 4.8% Y/Y and $20M above expectations. The company raised its FY2026 non-GAAP EPS guidance to $5.50–$5.56, exceeding consensus, while maintaining sales growth and raising adjusted EBITDA growth guidance.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are likely to drive short-term buying pressure.
Market read
Strong earnings and guidance raise for HSIC may attract momentum traders and impact sector peers.
What to watch
Potential supply-chain constraints or slower adoption of new products could temper growth.
Background
Henry Schein reported Q3 results beating EPS expectations and raised full-year guidance.
Ticker impact
Q3 Non-GAAP EPS $1.56 beat expectations and FY2026 EPS guidance raised to $5.50‑$5.56
likely upside as market prices in higher EPS expectations
Guidance lift exceeds consensus and follows a beat, indicating momentum.
Market effects
May boost confidence in dental and medical supply sector earnings outlook.
U.S. healthcare supply stocks could see modest gains.
Limited to U.S. investors; no direct global effect.
Counterpoint
If guidance is overly optimistic, future earnings could miss, leading to a pullback.
Key entities
- companyHenry Schein Inc.
U.S.-listed provider of health care products and services.
